The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...
A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company in a closely watched Phase 3 trial, causing shares to lose nearly a fifth of their value ...
Dec. 21, 2024 – Dec. 31, 2024 • New York, NY, USA, New York ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback